VectiveBio Holding AG’s IPO on Nasdaq

On 9 April 2021, VectivBio Holding AG announced its initial public offering and listing of its shares on Nasdaq (ticker symbol VECT). VectivBio is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Through its IPO, at USD 17 per share, VectivBio raises gross proceeds of USD 146.6 m (including greenshoe). At market close on the first day of trading, VectivBio had a market capitalization of USD 824m.